Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy.

Blood cell therapy Pub Date : 2023-11-25 DOI:10.31547/bct-2023-021

Masahiro Yoshida, Yoshinori Matsuoka, Satoshi Mitsuyuki, Noboru Yonetani, Junichi Kawai, Tadakazu Kondo, Takayuki Ishikawa

{"title":"Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy.","authors":"Masahiro Yoshida, Yoshinori Matsuoka, Satoshi Mitsuyuki, Noboru Yonetani, Junichi Kawai, Tadakazu Kondo, Takayuki Ishikawa","doi":"10.31547/bct-2023-021","DOIUrl":null,"url":null,"abstract":"Introduction: Cytokine release syndrome (CRS) is a life-threatening side effect of chimeric antigen receptor T (CAR-T) cell therapy. This study investigated whether serum inorganic phosphate (IP) and magnesium (Mg) levels are predictive markers of CRS development.Methods: This single-center retrospective cohort study enrolled 16 consecutive patients with diffuse large B-cell lymphoma who had received CAR-T cell therapy. Logistic regression models with generalized estimating equations were used to evaluate whether changes in IP and Mg levels from their baseline values were associated with the development of CRS within 48 hours.Results: Decreased IP and Mg levels from baseline (per 10% change) were associated with an increased CRS incidence (adjusted odds ratio 2.18 [95% confidence interval (CI), 1.31-3.62], 3.18 [95% CI, 1.57-6.44], respectively).Conclusions: Changes in IP and Mg concentrations within 48 hours may be useful predictive markers of CRS onset.","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 4","pages":"129-134"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10749729/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31547/bct-2023-021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cytokine release syndrome (CRS) is a life-threatening side effect of chimeric antigen receptor T (CAR-T) cell therapy. This study investigated whether serum inorganic phosphate (IP) and magnesium (Mg) levels are predictive markers of CRS development.

Methods: This single-center retrospective cohort study enrolled 16 consecutive patients with diffuse large B-cell lymphoma who had received CAR-T cell therapy. Logistic regression models with generalized estimating equations were used to evaluate whether changes in IP and Mg levels from their baseline values were associated with the development of CRS within 48 hours.

Results: Decreased IP and Mg levels from baseline (per 10% change) were associated with an increased CRS incidence (adjusted odds ratio 2.18 [95% confidence interval (CI), 1.31-3.62], 3.18 [95% CI, 1.57-6.44], respectively).

Conclusions: Changes in IP and Mg concentrations within 48 hours may be useful predictive markers of CRS onset.

Abstract Image

查看原文本刊更多论文

通过测量嵌合抗原受体 T 细胞疗法后的磷酸盐和镁水平，早期预测细胞因子释放综合征。

简介：细胞因子释放综合征（CRS）是一种威胁生命的副作用：细胞因子释放综合征（CRS）是嵌合抗原受体T（CAR-T）细胞疗法的一种危及生命的副作用。本研究探讨了血清无机磷酸盐（IP）和镁（Mg）水平是否是CRS发生的预测指标：这项单中心回顾性队列研究连续招募了16名接受过CAR-T细胞治疗的弥漫大B细胞淋巴瘤患者。结果：IP和Mg水平从基线值开始的变化与48小时内CRS的发生是否相关：结果：与基线值相比，IP和Mg水平的下降（每10%的变化）与CRS发生率的增加有关（调整后的几率比分别为2.18[95%置信区间（CI），1.31-3.62]，3.18[95%CI，1.57-6.44]）：48小时内IP和镁浓度的变化可能是CRS发病的有用预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood cell therapy

自引率

0.00%

发文量